JACC: CardioOncology Submission Guide: What to Prepare Before You Submit
Journal of the American College of Cardiology's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Assistant Professor, Cardiovascular & Metabolic Disease
Author context
Works across cardiovascular biology and metabolic disease, with expertise in navigating high-impact journal submission requirements for Circulation, JACC, and European Heart Journal.
Readiness scan
Before you submit to Journal of the American College of Cardiology, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Journal of the American College of Cardiology
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Journal of the American College of Cardiology accepts roughly ~5% of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach JACC: CardioOncology
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Confirm the manuscript is truly cardio-oncology in readership and consequence |
2. Package | Lock the article type, abstract, and disclosure material before upload |
3. Cover letter | Submit only when the first read makes the care impact obvious |
Quick answer: This JACC: CardioOncology submission guide starts with the real gate first: the online portal is not the hard part. The hard part is whether the paper is genuinely cardio-oncology. The official author guidance is unusually direct that every manuscript should answer one question: how does this work potentially impact the clinical care of cancer patients? If that answer is weak, the submission usually reads too general, too indirect, or too early for this journal.
From our manuscript review practice
Of manuscripts we review for cardio-oncology targets, the most common early failure is a paper that clearly touches both cancer and cardiovascular disease but does not yet make a strong case for changing cardio-oncology care.
JACC: CardioOncology: Key submission facts
Requirement | Details |
|---|---|
2024 JIF | 13.4 |
Quartile | Q1 |
Publisher | Elsevier in the JACC family |
Publishing model | Open access |
Submission route | Dedicated JACC: CardioOncology online submission system |
Core article types | Original Investigations, State-of-the-Art Reviews, Primers, Research Letters, Viewpoints, Clinical Case Challenges |
Scope test | Potential impact on the clinical care of cancer patients |
What JACC: CardioOncology is actually screening for
JACC: CardioOncology sits at a real boundary. That makes editorial fit harder, not easier.
Editors are usually asking:
- is this truly a cardio-oncology paper rather than a cardiology paper with cancer context
- does the result matter for cardiovascular care in patients with cancer
- is the translational or clinical consequence visible early
- would a cardio-oncology readership see this as practice-relevant, not just adjacent
That means audience discipline matters a lot. A study can be rigorous and still miss because its true readership is general cardiology, general oncology, or a narrower mechanistic venue.
The strongest submissions usually make the readership case obvious by the end of the abstract. Editors should not have to infer why a cardio-oncology team, and not just a cardiology or oncology team, needs this paper.
Before you submit
Pressure-test these questions before you open the portal:
- does the manuscript make a specific cardio-oncology care or decision consequence visible
- is the paper written for readers who actually manage or study cardiovascular issues in cancer patients
- would the cover letter explain the clinical impact in one clean sentence
- are relationships with industry, funding, and title-page details already stable
- does the paper fit one of the journal's article types honestly
If the manuscript only earns its cardio-oncology identity in the discussion, desk risk is high.
What the official materials make explicit
The live guide for authors is unusually helpful because it tells authors exactly what the journal expects the paper to do.
Official signal | Why it matters |
|---|---|
Every manuscript should answer how the work could impact the clinical care of cancer patients | This is the clearest first-read filter in the journal guidance |
Broad areas include mechanisms, model systems, therapeutics, epidemiology, precision medicine, and prevention | The journal spans preclinical to clinical work, but still wants a care-facing argument |
The journal has distinct article types including Original Investigations, Primers, and Clinical Case Challenges | The format has to match the real size and function of the story |
Relationship-with-industry disclosures belong on the title page | Administrative readiness is part of the first-submission package |
Submission is online only through the dedicated journal system | The package should be complete before upload, not assembled reactively |
The practical implication is simple: JACC: CardioOncology rewards papers that already know exactly why they belong there.
That also means format choice is part of fit. A manuscript pushed into the wrong article type often signals that the authors know the topic matters but have not yet decided what the real editorial unit of the story is.
Common failure patterns at this journal
1. The paper is really a general cardiology paper
Some manuscripts study heart failure, vascular toxicity, imaging, or biomarkers in cancer settings, but the real consequence is still general cardiology. Those papers often fit better in broader cardiology venues.
2. The paper is really a general oncology paper
Other manuscripts live inside drug development or oncology outcomes, with cardiovascular findings acting more like secondary context than the main readership hook.
3. The clinical implication is too indirect
Mechanistic or epidemiologic work can fit here, but the journal guidance keeps pointing back to clinical care. If the link to care is thin, authors often overestimate fit.
Before submission, a cardio-oncology readiness check can tell you whether the paper is failing on audience, consequence, or format.
Readiness check
Run the scan while Journal of the American College of Cardiology's requirements are in front of you.
See how this manuscript scores against Journal of the American College of Cardiology's requirements before you submit.
Cover letter and package checklist
Before you upload, make sure the package already answers these questions:
- what is the cardio-oncology care consequence
- why does the result matter specifically to clinicians and researchers managing cardiovascular disease in cancer
- which article type best matches the actual size and shape of the manuscript
- are title-page disclosures and funding statements complete
- does the abstract make the crossover importance legible quickly
At this level, the cover letter should not say only that the topic sits between cardiology and oncology. It has to explain what changes for cardio-oncology readers if the paper is published.
In our pre-submission review work with manuscripts targeting JACC: CardioOncology
In our pre-submission review work with manuscripts targeting JACC: CardioOncology, three patterns show up repeatedly before external review begins.
- The manuscript has overlap without ownership. It touches both cancer and cardiovascular medicine, but it has not decided which cardio-oncology problem it is solving.
- The paper reports association faster than actionability. We see many biomarker and outcomes manuscripts where the result is interesting but the care implication is still one inferential step too far away.
- The title and abstract undersell the real readership case. This journal is selective enough that a fuzzy first read can bury a genuinely good study.
A pre-submission cardio-oncology fit check is useful here because many avoidable misses are positioning errors, not fatal science errors.
JACC: CardioOncology versus nearby alternatives
Journal | Best fit | Think twice if |
|---|---|---|
JACC: CardioOncology | Cardio-oncology work with a clear cardiovascular-care consequence in patients with cancer | The paper is mostly cardiology or mostly oncology with only thin crossover value |
JACC | Broad cardiovascular consequence beyond the cancer-care boundary | The main readership is specifically cardio-oncology |
Journal of Clinical Oncology | Oncology-led work where the cardiovascular findings support a broader oncology question | The real audience is cardiovascular clinicians |
European Heart Journal | Cardiology-led work with broad cardiovascular practice importance | The manuscript's identity depends on cancer-therapy context |
The journal choice should follow the paper's real readers, not the fact that two specialties appear in the same dataset.
Submit If
- the manuscript clearly changes a cardio-oncology care, management, or translational conversation
- the title and abstract make that consequence visible quickly
- the paper fits one of the journal's article types honestly
- the cardio-oncology readership is the obvious primary audience
- disclosures, funding, and title-page details are already stable
Think Twice If
- the manuscript is fundamentally a general cardiology paper with cancer context
- the manuscript is fundamentally an oncology paper with cardiovascular side observations
- the main result is descriptive biomarker or association work without a strong care implication
- the cardio-oncology fit only becomes convincing late in the discussion
Before upload, run a cardio-oncology first-read check to see whether the paper truly belongs here.
Frequently asked questions
JACC: CardioOncology uses its dedicated online submission system. The operational route is simple, but the manuscript still has to behave like true cardio-oncology research rather than a general cardiology or oncology paper with a thin crossover frame.
The official guide says every manuscript type should answer the question, 'How does this work potentially impact the clinical care of cancer patients?' Editors are usually screening for a real clinical or translational cardio-oncology consequence, not just overlap between two fields.
The journal publishes Original Investigations, State-of-the-Art Reviews, Primers in Cardio-Oncology, Research Letters, Viewpoints, Clinical Case Challenges, and Letters to the Editor. Choosing the right format matters because the journal is explicit about article types.
Common reasons include a paper that is mainly general cardiology, mainly general oncology, or mainly biomarker description without a clear implication for cardiovascular care in patients with cancer.
Sources
Final step
Submitting to Journal of the American College of Cardiology?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
Supporting reads
Conversion step
Submitting to Journal of the American College of Cardiology?
Anthropic Privacy Partner. Zero-retention manuscript processing.